Genomic Classification and Prognosis in Acute Myeloid Leukemia
By E. Papaemmanuil, Moritz Gerstung, L. Bullinger, V. Gaidzik, P. Paschka, Nicola D. Roberts, N. Potter, M. Heuser, F. Thol, N. Bolli and 17 more. New England Journal of Medicine, 2016
3,531 citations recorded by the source corpus.
Background Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice. Methods We enrolled a total of 1540 patients in three prospective trials of intensive therapy. Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, we defined AML genomic subgroups and their relevance to clinical outcomes. Results We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients. Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clinical outcomes. In addition to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2R172 mutations (in 1%). Patients with chromatin–spliceosome and TP53–aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome. In addition to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival. The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations. Such gene–gene interactions were especially pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis. These predictions require validation in prospective clinical trials. Conclusions The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.)
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/c32c556c0e4046d71acd6e563fb57ee6f74b7787
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling (2017, background): “80% of grade II-III gliomas and secondary glioblastoma (GBM), 10%–20% of acute myeloid leukemia (AML) patients, and at a lower rate in other cancers; most of these lesions involve mutations of arginine (R) residues in codon 132 for IDH1 (IDH1R132) and residues 140 and 172 for IDH2 (IDH2R140 and IDH2”
- Acute myeloid leukemia: current progress and future directions (2021, background): “Interestingly, patients with t (8; 21) may have persistent MRD at levels below 0.”
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018, methodology): “Preparation of samples There are 2 major approaches for preparing BM samples for FCM: (1) stain/lyse/wash (or no wash) has the advantage of reducing cell losses; and (2) bulk lysis fol- lowed by washing and staining (and washing) has the advantage of having all tubes prepared in a similar way for th”
- Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and impacts clinical outcome (2017, background): “Presumptive Driver Mutations Comparing CHmutations to the genesmost commonly altered in acute myeloid leukemia (AML) from prior published series (Papaemmanuil et al., 2016), we observed a significant degree of variation in the distribution of CH mutations (Figure S2).”
- Cancer therapy shapes the fitness landscape of clonal hematopoiesis (2020, positive): “In 91% of cases, transformation was associated with acquisition of additional somatic mutations, including chromosomal aneuploidies or mutations in genes (e.g. FLT3, KRAS, NRAS) known to drive late progression to myeloid disease 27,32–34 (Supplementary Figure 11).”
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017, methodology): “RUNX1 mutations although occurring with unfavorable features, such as older age, antecedent myeloid disorder, and concurrent gene mutations (eg, SRSF2, ASXL1), identify patients with poor prognosis.(20-23,37,70,73) Likewise, ASXL1 mutations are more common in older patients and associated with infer”
- Machine learning and feature selection for drug response prediction in precision oncology applications (2018, background): “the detection of statistically associated multi-gene interactions in genomic-based studies, which can be restricted to a single cancer type (Papaemmanuil et al. 2016).”